Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3592513 | 0.87 | ALDH1A1 (0.47) | GRIN2BCCR3TSHRALDH1A1FAAH | |
| SCHEMBL3604179 | 0.86 | CCR3 (0.46) | CCR3FAAHUSP30 | |
| SCHEMBL3601902 | 0.86 | ALDH1A1 (0.47) | MAPK1CCR3TSHRALDH1A1HPGD | |
| SCHEMBL3601798 | 0.86 | CCR3 (0.52) | CYP2D6HSD17B10CCR3CYP2C19CYP3A4 | |
| SCHEMBL3609998 | 0.86 | PARP14 (0.48) | CCR3ALDH1A1USP30 | |
| SCHEMBL3605934 | 0.85 | NAMPT (0.48) | CCR3USP30 | |
| SCHEMBL3600238 | 0.85 | USP30 (0.49) | CYP2D6CCR3CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL3608614 | 0.85 | CCR3 (0.59) | MAPK1GRIN2BCCR3TSHRALDH1A1 | |
| SCHEMBL3596926 | 0.84 | MAPT (0.51) | CCR3CYP3A4CYP1A2TSHRUSP30 | |
| SCHEMBL3615203 | 0.84 | MAPT (0.49) | GRIN2BCCR2CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | HTR2C, HTR5A, HTR2A | CYP2D6 771/4885HSD17B10 1707/4885MAPK1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.